
- /
- Supported exchanges
- / US
- / NCNA.NASDAQ
NuCana PLC (NCNA NASDAQ) stock market data APIs
NuCana PLC Financial Data Overview
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get NuCana PLC data using free add-ons & libraries
Get NuCana PLC Fundamental Data
NuCana PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -17 171 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NuCana PLC News

NuCana to implement 1:200 reverse ADS split to boost share price
EDINBURGH - NuCana plc (NASDAQ:NCNA) announced Friday it will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from 1:25 to 1:5,000, effectively creating a 1:200 reverse AD...


NuCana Announces Plan to Implement ADS Ratio Change
EDINBURGH, United Kingdom, July 11, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“A...

NuCana Announces Plan to Implement ADS Ratio Change
EDINBURGH, United Kingdom, July 11, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“ADS...

NuCana CEO takes leave of absence due to health reasons
NuCana plc (NASDAQ:NCNA) announced today that Chief Executive Officer Hugh S. Griffith will be taking a leave of absence due to health reasons, effective immediately. Griffith is expected to return t...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.